The clinician should review the prognosis of the condition and potential changes in medical management (e.g., no treatment in GCK- hyperglycemia and sulfonylurea treatment with HNF1A and HNF4A monogenic diabetes8,97. This evidence concerns the gene HNF1A and Hyperglycemia.